PRIMAEGISresearch
← Scenarios
SAKAR

Sakar Healthcare Limited

Pharmaceuticals: Major/ NSE
Compiled

Auto-generated from filings and public channels — no analyst dossier.

If management delivers what it guided

arithmetic on filed guidance and past valuations · not a price target
SAKAR
FY26 → FY27 · 1 year of guidance · ~0.7 years from today₹885 today
BEAR
₹269
-70%
23.1% a year · 15.9x exit
BASE
₹567
-36%
40% a year · 29.6x exit
BULL
₹932
+5%
54.4% a year · 44.1x exit
FY27TODAY₹885 today₹932₹269₹567
Where the market has priced it
8x65x today70x
  • the guided figure reached earnings through a low-confidence bridge
  • the last 3 years priced this company 27% above its ten-year median (38x vs 30x) — the exit multiple here is the ten-year one, so a sustained re-rating would not be captured
  • at 65x its FY26 earnings the stock already trades above the top of its own ten-year range (44x)
  • the range is unusually wide — read it as the span of management's own claim, not as a forecast
How these numbers are produced
Earnings baseFY26 fiscal year EPS ₹13.7 (screener)
Guided growth40% a year, said on the call of 22-May-2026 · transcript
Read across asoperating: unlabelled growth figure, read as revenue — low confidence
Delivery calibration0.58x / 1x / 1.36x of what was guided — measured: 76 annual guided-vs-filed pairs + 77 near-complete quarterly years — NSE transcripts against the companies' own filings
Exit multiple15.92x / 29.55x / 44.08x, this company’s own p20 / median / p80 across 10 filed years
Filed-industry peersmedian 29.14x across 38 peers — the cross-check, not the input
Arithmeticbase EPS × (1 + guided growth × delivery)1 × exit multiple
Arithmetic on management’s own guidance and this company’s own past valuations. Not a price target, not a recommendation, and not a forecast of what the stock will do.

What management said

from a third-party research digest · not our own extraction
implied earnings growth 40%
Expecting 40% year-on-year growth in FY27, with oncology contributing 60-65% of revenue (38% in FY26) and exports becoming the dominant revenue source. Long-term goal of INR800-1,000 crores revenue at optimal utilization.
Call 22-May-2026 · bridge confidence low · transcript PDF